Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC2 | O75106 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7286911 | 0.83 | AOC2 (0.34) | AOC2TSHRMAOBKDM4EALDH1A1 | |
| SCHEMBL26415058 | 0.80 | P2RX7 (0.37) | AOC2TSHRMAOBP2RX7 | |
| SCHEMBL11105046 | 0.78 | KMT2A (0.38) | AOC2TSHRKDM4EALDH1A1 | |
| SCHEMBL3713600 | 0.76 | MEN1 (0.43) | AOC2TSHRMAOBKDM4E | |
| SCHEMBL16040115 | 0.75 | KDM4E (0.33) | AOC2TSHRKDM4E | |
| SCHEMBL7281438 | 0.75 | AOC2 (0.32) | AOC2KDM4E | |
| SCHEMBL31642338 | 0.75 | NPC1 (0.42) | AOC2KDM4EALDH1A1 | |
| SCHEMBL7287440 | 0.74 | CYP3A4 (0.35) | AOC2MAOBALDH1A1 | |
| SCHEMBL22833643 | 0.74 | LMNA (0.39) | AOC2TSHRMAOBKDM4E | |
| SCHEMBL22648261 | 0.72 | AOC2 (0.35) | AOC2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117897384-A | CDK2 inhibitors | 缆图药品公司 | 2024-04-16 | — | — | CN | disclosed |
| US-20230130822-A1 | LOW TOXICITY NMP SUBSTITUTES AND USES THEREOF | ADVANCION CORPORATION | 2023-04-27 | — | — | US | disclosed |
| EP-4103550-A2 | LOW TOXICITY NMP SUBSTITUTES AND THEIR PREPARATION | ANGUS Chemical Company (US) | 2022-12-21 | — | — | EP | disclosed |
| CN-115335360-A | Low toxicity NMP substitutes and their preparation | 安格斯化学公司 | 2022-11-11 | — | — | CN | disclosed |
| CN-109803962-B | Modulators of cystic fibrosis transmembrane conductance regulator proteins, and pharmaceutical compositions | 弗特克斯药品有限公司 | 2022-04-29 | — | — | CN | disclosed |
| WO-2021163348-A2 | LOW TOXICITY NMP SUBSTITUTES AND USES THEREOF | ANGUS CHEMICAL COMPANY (US) | 2021-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230130822-A1 | LOW TOXICITY NMP SUBSTITUTES AND USES THEREOF | NME4, NMBR, NMUR1 | AOC2 2578/4885TSHR 3306/4885MAOB 878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.